Entering text into the input field will update the search result below

Nektar Therapeutics: The Gift That Keeps On Giving


  • Nektar reported robust Q4 earnings that beat the Wall Street estimate by a sizable margin.
  • Despite the vast number of catalysts, we’ll feature NKTR-214.
  • The recent partnership with Bristol-Myers Squibb to co-develop NKTR-214 in 20 different cancer indications will procure many blockbusters.

If the job has been correctly done when a common stock is purchased, the time to sell it is – almost never. - The Father of Growth Investing (Philip Fisher)

On March 2, 2018, Nektar Therapeutics (NASDAQ:NASDAQ:NKTR) - a bioscience that focuses on the innovation and launch of novel medicines to service cancer, autoimmune disease, and chronic pain - catapulted to its new 52-week high. As follows, the stock traded $18.32 higher at $102.87% for the 21% profits in response to a robust earnings report. Much of the aforementioned share price appreciation is due to multiple powerful catalysts. In this research, we’ll go over Fiscal 2017 earnings highlight (as well as the key catalysts to power further upsides).

Figure 1: Nektar stock chart. (Source: StockCharts).

Fundamentals Analysis

Based in San Francisco, CA, Nektar leverages on its proven chemistry platform to design novel medicines (as depicted figure 2). Notably, the “honeycomb” of Nektar is its global leadership in polymer chemistry that, in and of itself, is a powerful therapeutic designing tool. In exploiting the structural adeptness of polymers, Nektar can customize the behavior of drugs (to a great extent). And, the targeting of well-characterized pathways enabled its innovation efforts to have the best chances of yielding meaningful clinical benefits.

Figure 2: Therapeutic pipeline. (Source: Dr. Tran BioSci).

Earnings Highlight

For 4Q2017, Nektar procured $95.5M in revenues, which is 153% higher than the $37.5M for the same period a year prior. The said figure beat Wall Street’s expectation of $31.5M by far, thereby causing the stock to rally as elucidated. For Fiscal 2017, total revenues came in at $307.7M compared to $165.4M for 2016, thus representing the whopping 186% improvement year-over-year. Interestingly, the $130.1M (out of $150M) in total upfront payment realized from Eli Lilly & Company (NYSE:LLY) for the

Author’s Notes: We’re honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (“IBI”) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 446%, 180%, 180%, and 82% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Subscribe to our marketplace now to lock in the current price and save money in the future.

This article was written by

The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I like to inform our readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.